ProPublica

Journalism in the Public Interest

Cancel

Prescriber Checkup

At A Glance: This Prescriber in 2012

Specialist

Self-Reported Primary Specialty

See Other Prescribers With This Specialty in This State »

9,288Medicare Part D Prescriptions Filled, Including Refills

Rank: 7 out of 326

$676K Total Retail Price of All Prescriptions

Rank: 22 out of 326

524 Patients Receiving at Least One Drug in Part D
72%Patients 65 Years and Older
41% Subsidized Claims for Low-Income Patients

How Does This Prescriber Compare to Peers?

In the same specialty and state. Caveats »

Drugs That Present Special Risks
Costs of Prescribing
Higher avg Average for
this specialty
in Michigan
Lower avg

Schedule Two
Controlled Substances

13% of this provider’s 524 patients filled at least one prescription for a schedule two drug, compared to an average of 5%.

Schedule Three
Controlled Substances

21% of this provider’s 524 patients filled at least one prescription for a schedule three drug, compared to an average of 16%.

Risky Drugs to Seniors

1% of this provider’s 6,498 prescriptions for patients 65 and older were for "potentially dangerous" drugs, compared to an average of 2%.

Brand Name Drugs

18% of this provider’s prescriptions were for brand-name drugs, compared to an average of 24%.

Prescription Price

$73 was the average price of a prescription from this provider, compared to $104 among peers.

Prescriptions per Patient

18 is the average number of prescriptions (including refills) per patient, compared to an average of 9.


Another View

This chart shows a different comparison of all providers in this specialty based on their mix of drugs and volume. Providers are grouped by similarity; those least like their peers are farthest to the right. Hover over the bars to see names of other prescribers.

← Prescribers more like their peers Prescribers less like their peers →
KEY: How to read this
chart

Fewer Prescribers
More Prescribers

This Prescriber
Hover to see more prescribers

This Prescriber's Drugs

The table below list this provider’s drugs, the number of prescriptions and how many went to seniors. Drugs are ranked by volume and compared with the rank for all providers in the same specialty and state.

Click to Filter by Category

Clear Filter


S2

A schedule two drug. More » Schedule two drugs have a high potential for abuse and severe dependence, according to the Drug Enforcement Administration.

S3

A schedule three drug. More » Schedule three drugs have potential for abuse and dependence, according to the Drug Enforcement Administration.

A

An antipsychotic drug. More » Antipsychotics are frequently given to dementia patients, though it increases their risk of death.

R

A risky drug for seniors. More » The American Geriatrics Society has said this drug is "potentially dangerous" for seniors and might be inappropriate.

10

This provider is among the top 10 prescribers of
this drug in the country.

This provider’s prescriptions for this drug were for more days than those of peers. More » Because of this, his or her prescription count may be lower.

This provider’s prescriptions for this drug were for fewer days than those of peers. More » Because of this, his or her prescription count may be higher.

This Drug's Rank
Drug Name Total Prescriptions Filled
Including Refills
Prescriptions
to 65+
Category For this Prescriber For All Prescribers in
This Specialty in Michigan
HYDROCODONE-ACETAMINOPHEN 641 309 S3 1 1
OMEPRAZOLE 393 280 2 5
LISINOPRIL 360 265 3 3
SIMVASTATIN 351 300 4 2
LEVOTHYROXINE SODIUM 298 216 5 4
METOPROLOL TARTRATE 245 202 6 6
AMLODIPINE BESYLATE 182 140 7 8
FUROSEMIDE 172 144 8 7
METFORMIN HCL 157 118 9 16
GABAPENTIN 157 103 9 17
FENTANYL 156 78 S2 11 47
TRIAMTERENE-HCTZ 154 132 12 72
TRAMADOL HCL 126 107 13 28
WARFARIN SODIUM 124 118 14 11
POTASSIUM CHLORIDE 115 87 15 21
MORPHINE SULFATE ER 110 14 S2 16 38
ATORVASTATIN CALCIUM 109 90 17 10
METOPROLOL SUCCINATE 103 95 18 9
TERAZOSIN HCL 95 91 19 267
SERTRALINE HCL 92 68 20 35
OXYCONTIN 90 0 S2 21 99
ZOLPIDEM TARTRATE 84 58 22 30
TAMSULOSIN HCL 80 73 23 29
OXYCODONE HCL-ACETAMINOPHEN 79 24 S2 24 133
HYDROCHLOROTHIAZIDE 75 58 25 24
CARBIDOPA-LEVODOPA 73 40 26 58
LOSARTAN POTASSIUM 71 56 27 14
ALENDRONATE SODIUM 69 56 28 41
OXYCODONE HCL 69 0 S2 28 40
PREDNISONE 59 42 30 18
CYCLOBENZAPRINE HCL 59 18 R 30 95
IBUPROFEN 59 14 30 62
ATENOLOL 59 51 30 13
AMOXICILLIN 58 34 34 148
CIPROFLOXACIN HCL 57 36 35 52
GLIPIZIDE 57 44 35 106
CEPHALEXIN 56 36 37 90
RISPERIDONE 55 37 38 51
SULFAMETHOXAZOLE-TRIMETHOPRIM 54 34 39 112
NAPROXEN 52 32 40 137
OXYBUTYNIN CHLORIDE ER 52 48 40 203
FENOFIBRATE 52 44 40 141
ALLOPURINOL 52 48 40 44
About This Data

ProPublica obtained prescribing data from Medicare’s prescription drug benefit, known as Part D, under the Freedom of Information Act. The data for 2012 includes more than 1.2 billion prescriptions written by nearly 1.5 million doctors, nurses and other providers. This database lists about 382,000 of those providers who wrote 50 or more prescriptions for at least one drug that year. Almost three-fourths went to patients 65 and older; the rest were for disabled patients. Methodology »

Incorrect Info?

If you are a provider and you believe your address is incorrect, check the listing you created on the National Provider Identifier registry. If you change your listing, send a note to drugs@propublica.org and we will update your information. If you have other questions about this data, send a note to drugs@propublica.org.

Caveats
  • No comparisons are shown if 10 or fewer prescribers in the state share this specialty.
  • The list of top drugs includes only those for which this provider wrote 50 or more prescriptions, but all prescriptions are counted in the summary totals at the top.
  • The calculation of “Risky Drugs to Seniors” does not include drugs for which a provider wrote 11 or fewer prescriptions because Medicare redacted the information to protect patient privacy.
  • Comparisons do not take into account the medical conditions of patients. Medications for certain conditions do not have generic alternatives, so patients would receive more expensive brand name drugs.
  • This provider's address and specialty information was last updated on July 8, 2007.
  • Comparisons are based on each provider’s current address, not necessarily where he or she worked during the time period covered in this database.